News

Filter by category

Press Published: July 7, 2026

Simplexia initiates preparatory clinical study ahead of planned Phase 1/2a HSV-2 vaccine trial
Publications Published: July 10, 2026

Glycoprotein G enables HSV-2 neuroinvasion and provides protection as a glycosylated vaccine antigen
Event Published: March 18, 2026

Simplexia to Attend BIO-Europe Spring and LSX World Congress in Lisbon
Press Published: October 30, 2025

Simplexia launches CEO search as it secures bridge funding to complete clinical preparations
Event Published: November 4, 2024

Simplexia will participate in RESI London 2024 | 4 December London
Event Published: October 4, 2024

Simplexia will participate in Bio Europe 2024 | 4-6 November Stockholm
Event Published: September 28, 2024

Simplexia will participate in World Vaccine Congress 2024 | October 28–31 Barcelona
Event Published: August 18, 2024

Simplexia will participate in NLS Days 2024 | 18-19 September Malmö
Publications Published: October 23, 2023

Herpes Simplex Virus Type 2 Mucin-Like Glycoprotein mgG Promotes Virus Release from the Surface of Infected Cells.
Event Published: October 20, 2023

Simplexia will participate in Nordic Life Sciences Days – NLS Days 2023 | 29 – 30 November 2023
Event Published: October 10, 2023

Simplexia will participate in BioEurope 2023 | 8 – 9 November 2023
Publications Published: October 2, 2023

A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection.
Event Published: October 2, 2023

Simplexia will participate in World Vaccine Congress Europe 2023 | 16 – 19 October 2023